You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Details for New Drug Application (NDA): 019123


✉ Email this page to a colleague

« Back to Dashboard


NDA 019123 describes KLOR-CON, which is a drug marketed by Upsher Smith Labs and is included in four NDAs. It is available from five suppliers. Additional details are available on the KLOR-CON profile page.

The generic ingredient in KLOR-CON is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
Summary for 019123
Tradename:KLOR-CON
Applicant:Upsher Smith Labs
Ingredient:potassium chloride
Patents:0
Pharmacology for NDA: 019123
Mechanism of ActionOsmotic Activity
Physiological EffectIncreased Large Intestinal Motility
Inhibition Large Intestine Fluid/Electrolyte Absorption
Suppliers and Packaging for NDA: 019123
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5315 0245-5315-01 100 BLISTER PACK in 1 BLISTER PACK (0245-5315-01) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (0245-5315-89)
KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5315 0245-5315-11 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-5315-11)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength8MEQ
Approval Date:Apr 17, 1986TE:AB2RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Apr 17, 1986TE:AB2RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links